We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Allergan's Depression Candidate Fails in Studies, Stock Down
Read MoreHide Full Article
Allergan plc announced that three acute pivotal studies on depression candidate, rapastinel, failed to meet their primary endpoint. The studies were evaluating rapastinel, its NMDA receptor modulator, as an adjunctive treatment of major depressive disorder (MDD) compared to placebo, both in combination with antidepressant therapy (ADT)
In the studies, the rapastinel treatment arms did not differentiate from placebo on the primary and key secondary endpoints. Rapastinel is also being evaluated as a monotherapy treatment for MDD in phase III and for treating MDD patients at imminent risk of suicide in phase II. After evaluating the impact of the data from the failed studies, Allergan said it will make a decision on these monotherapy studies this year.
Allergan’s stock was down 1.9% in response to the news. Allergan’s share price has risen 2.9% this year so far compared with the industry’s increase of 8.3%.
Please note that Rapastinel was granted breakthrough therapy status for MDD by the FDA in 2016 and was considered by Allergan to be a potentially game-changing treatment.
However, making drugs to treat mental disorders is extremely challenging and there have been several failures in the past.
Last month, the FDA gave a complete response letter to Alkermes plc’s (ALKS - Free Report) new drug application looking for approval for ALKS 5461, a once-daily oral medication for adjunctive treatment of MDD.
However, the depression market has had its share of successes as well. Earlier this week, J&J (JNJ - Free Report) gained FDA approval for its new nasal spray, Spravato (esketamine) for treatment-resistant depression (TRD). The nasal spray has been approved for use in conjunction with an oral antidepressant in patients with MDD who have not benefited from multiple standard treatments. Approximately, one-third of U.S. adults with MDD are considered to have TRD as they have not found relief with at least two different antidepressants and could benefit from Spravato.
The depression market is quite large and has many players. Allergan itself has a couple of products in its portfolio, Vraylar and, Viibryd. Eli Lilly (LLY - Free Report) markets depression drugs like Cymbalta, Prozac and Zyprexa.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Image: Bigstock
Allergan's Depression Candidate Fails in Studies, Stock Down
Allergan plc announced that three acute pivotal studies on depression candidate, rapastinel, failed to meet their primary endpoint. The studies were evaluating rapastinel, its NMDA receptor modulator, as an adjunctive treatment of major depressive disorder (MDD) compared to placebo, both in combination with antidepressant therapy (ADT)
In the studies, the rapastinel treatment arms did not differentiate from placebo on the primary and key secondary endpoints. Rapastinel is also being evaluated as a monotherapy treatment for MDD in phase III and for treating MDD patients at imminent risk of suicide in phase II. After evaluating the impact of the data from the failed studies, Allergan said it will make a decision on these monotherapy studies this year.
Allergan’s stock was down 1.9% in response to the news. Allergan’s share price has risen 2.9% this year so far compared with the industry’s increase of 8.3%.
Please note that Rapastinel was granted breakthrough therapy status for MDD by the FDA in 2016 and was considered by Allergan to be a potentially game-changing treatment.
However, making drugs to treat mental disorders is extremely challenging and there have been several failures in the past.
Last month, the FDA gave a complete response letter to Alkermes plc’s (ALKS - Free Report) new drug application looking for approval for ALKS 5461, a once-daily oral medication for adjunctive treatment of MDD.
However, the depression market has had its share of successes as well. Earlier this week, J&J (JNJ - Free Report) gained FDA approval for its new nasal spray, Spravato (esketamine) for treatment-resistant depression (TRD). The nasal spray has been approved for use in conjunction with an oral antidepressant in patients with MDD who have not benefited from multiple standard treatments. Approximately, one-third of U.S. adults with MDD are considered to have TRD as they have not found relief with at least two different antidepressants and could benefit from Spravato.
The depression market is quite large and has many players. Allergan itself has a couple of products in its portfolio, Vraylar and, Viibryd. Eli Lilly (LLY - Free Report) markets depression drugs like Cymbalta, Prozac and Zyprexa.
Allergan currently has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Is Your Investment Advisor Fumbling Your Financial Future?
See how you can more effectively safeguard your retirement with a new Special Report, “4 Warning Signs Your Investment Advisor Might Be Sabotaging Your Financial Future.”
Click to get it free >>